Optimising low-dose methotrexate for rheumatoid arthritis-A review

被引：46
作者：
Lucas, Catherine J. [1 ,2 ,3 ]
Dimmitt, Simon B. [1 ,4 ]
Martin, Jennifer H. [1 ,2 ,3 ]
机构：
[1] Univ Newcastle, Sch Med & Publ Hlth, Discipline Clin Pharmacol, Newcastle, NSW, Australia
[2] Hunter Med Res Inst, Newcastle, NSW, Australia
[3] Hunter New England Local Hlth Dist, Newcastle, NSW, Australia
[4] Univ Western Australia, Fac Hlth & Med Sci, Med Sch, Div Internal Med, Nedlands, WA, Australia
来源：
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY | 2019年 / 85卷 / 10期
关键词：
clinical pharmacology; methotrexate; pharmacodynamics; pharmacokinetics; prescribing; rheumatoid arthritis; MODIFYING ANTIRHEUMATIC DRUGS; PULSE METHOTREXATE; SUBCUTANEOUS METHOTREXATE; ORAL METHOTREXATE; DISEASE-ACTIVITY; DOUBLE-BLIND; RISK-FACTORS; POLYGLUTAMATE CONCENTRATIONS; COMBINATION THERAPY; AMERICAN-COLLEGE;
D O I：
10.1111/bcp.14057
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
Methotrexate at low doses (5-25 mg/week) is first-line therapy for rheumatoid arthritis. However, there is inter- and intrapatient variability in response, with contribution of variability in concentrations of active polyglutamate metabolites, associated with clinical efficacy and toxicity. Prescribing remains heterogeneous across population groups, disease states and regimens. This review examines current knowledge of dose-response of oral methotrexate in the setting of rheumatoid arthritis, and how this could help inform dosage regimens.
引用
收藏
页码：2228 / 2234
页数：7
相关论文
共 95 条
[1]   METHOTREXATE IN RHEUMATOID-ARTHRITIS - TOXIC EFFECTS AS THE MAJOR FACTOR IN LIMITING LONG-TERM TREATMENT [J].
ALARCON, GS ;
TRACY, IC ;
BLACKBURN, WD .
ARTHRITIS AND RHEUMATISM, 1989, 32 (06) :671-676
[2]   Remission and active disease in rheumatoid arthritis - Defining criteria for disease activity states [J].
Aletaha, D ;
Ward, MM ;
Machold, KP ;
Nell, VPK ;
Stamm, T ;
Smolen, JS .
ARTHRITIS AND RHEUMATISM, 2005, 52 (09) :2625-2636
[3]   Diagnosis and Management of Rheumatoid Arthritis A Review [J].
Aletaha, Daniel ;
Smolen, Josef S. .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2018, 320 (13) :1360-1372
[4]   WEEKLY PULSE METHOTREXATE IN RHEUMATOID-ARTHRITIS - CLINICAL AND IMMUNOLOGICAL EFFECTS IN A RANDOMIZED, DOUBLE-BLIND-STUDY [J].
ANDERSEN, PA ;
WEST, SG ;
ODELL, JR ;
VIA, CS ;
CLAYPOOL, RG ;
KOTZIN, BL .
ANNALS OF INTERNAL MEDICINE, 1985, 103 (04) :489-496
[5]  
Australian Rheumatology Association, 2016, GUID PRESCR LOW DOS
[6]   Methotrexate Catabolism to 7-Hydroxymethotrexate in Rheumatoid Arthritis Alters Drug Efficacy and Retention and Is Reduced by Folic Acid Supplementation [J].
Baggott, Joseph E. ;
Morgan, Sarah L. .
ARTHRITIS AND RHEUMATISM, 2009, 60 (08) :2257-2261
[7]   Genetic polymorphism of the methotrexate transporter ABCG2, blood pressure and markers of arterial function in patients with rheumatoid arthritis: repeated cross-sectional study [J].
Baghdadi, Leena R. ;
Woodman, Richard J. ;
Shanahan, E. Michael ;
Wiese, Michael D. ;
Mangoni, Arduino A. .
PHARMACOGENOMICS & PERSONALIZED MEDICINE, 2018, 11 :205-210
[8]   Clinical pharmacokinetics of low-dose pulse methotrexate in rheumatoid arthritis [J].
Bannwarth, B ;
Pehourcq, F ;
Schaeverbeke, T ;
Dehais, J .
CLINICAL PHARMACOKINETICS, 1996, 30 (03) :194-210
[9]   Analysis of Intracellular Methotrexate Polyglutamates in Patients With Juvenile Idiopathic Arthritis Effect of Route of Administration on Variability in Intracellular Methotrexate Polyglutamate Concentrations [J].
Becker, Mara L. ;
van Haandel, Leon ;
Gaedigk, Roger ;
Lasky, Andrew ;
Hoeltzel, Mark ;
Stobaugh, John ;
Leeder, J. Steven .
ARTHRITIS AND RHEUMATISM, 2010, 62 (06) :1803-1812
[10]   Meta-Regression of a Dose-Response Relationship of Methotrexate in Mono- and Combination Therapy in Disease-Modifying Antirheumatic Drug-Naive Early Rheumatoid Arthritis Patients [J].
Bergstra, S. A. ;
Allaart, C. F. ;
Stijnen, T. ;
Landewe, R. B. M. .
ARTHRITIS CARE & RESEARCH, 2017, 69 (10) :1473-1483
12345678910